Industry Deep-Dive: Diagnostic Testing for 5-ARD (SRD5A2 Mutations) in Newborns, Children, and Adults
Global Leading Market Research Publisher QYResearch announces the release of its latest report “5-Alpha Reductase Deficiency – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global 5-Alpha Reductase Deficiency market, including market size, share, demand, industry development status, and forecasts for the next few years.
Core User Pain Point & Solution Direction: Pediatric endocrinologists, urologists, and clinical geneticists face a critical diagnostic challenge: 5-alpha reductase deficiency (5-ARD) is a rare autosomal recessive disorder caused by SRD5A2 gene mutations, impairing conversion of testosterone to dihydrotestosterone (DHT), leading to ambiguous genitalia in 46,XY newborns, male infertility, and under-virilization. Delayed or incorrect diagnosis results in inappropriate gender assignment, psychosocial distress, and suboptimal treatment outcomes. Diagnostic testing for 5-alpha reductase deficiency includes chromosome analysis (karyotyping to confirm 46,XY), gene sequencing (SRD5A2 mutation analysis), hormone tests (testosterone-to-DHT ratio, elevated >20-30:1), and imaging (pelvic ultrasound to identify internal reproductive structures). Accurate diagnosis enables informed decisions regarding gender assignment, hormone replacement therapy (testosterone or DHT), surgical correction (hypospadias repair, gonadectomy), and genetic counseling for families.
Global Market Size & Growth Trajectory
The global market for 5-Alpha Reductase Deficiency was estimated to be worth US320millionin2025andisprojectedtoreachUS320millionin2025andisprojectedtoreachUS 520 million, growing at a CAGR of 7.2% from 2026 to 2032. Market growth is driven by expanding newborn screening programs for disorders of sexual development (DSD), declining cost of genetic sequencing (whole exome, whole genome, targeted gene panels), increased awareness of 5-ARD in regions with consanguineous marriage (Middle East, North Africa, South Asia), and advances in prenatal diagnosis.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/5983901/5-alpha-reductase-deficiency
Market Share & Competitive Landscape
The market features a consolidated landscape with large pharmaceutical companies, diagnostic manufacturers, and specialty genetics laboratories:
- Merck & Co. (US/Germany) – Global leader, approximately 15% market share (legacy hormone testing, androgen assays).
- F. Hoffmann-La Roche (Switzerland) – Approximately 12% share. Strong in molecular diagnostics (PCR, sequencing platforms).
- Pfizer Inc. (US) – Approximately 10% share (legacy endocrinology and hormone therapeutics).
- Sanofi SA (France) – Approximately 8% share.
- GlaxoSmithKline (UK) – Approximately 6% share.
- Novartis, Bayer, Eli Lilly – Pharmaceutical and diagnostic suppliers.
- Alma Lasers, Viveve Solution, Fotona – Laser and aesthetic device manufacturers (adjacent to DSD surgical management).
- Almirall, Hologic – Diagnostic equipment and women’s health.
The top three (Merck, Roche, Pfizer) account for approximately 37% of global market share.
Type Segmentation by Diagnostic Method
- Hormone Tests (45% share) – Largest segment, 6.5% CAGR. Serum testosterone, DHT, and testosterone-to-DHT ratio (baseline and after hCG stimulation). Ratio >20-30:1 (normal <15:1) suggests 5-ARD. Cost: US$ 50-200 per test. Requires specialized LC-MS/MS assays (DHT low concentration, cross-reactivity with testosterone). Available in most endocrinology reference labs.
- Gene Sequencing (30% share) – Fastest-growing segment (11.2% CAGR). Sanger sequencing (targeted SRD5A2 gene), whole exome sequencing (WES), whole genome sequencing (WGS). Identifies specific mutations (over 100 known SRD5A2 mutations). Critical for definitive diagnosis, carrier detection, prenatal diagnosis. Cost declining: Sanger US200−500,WESUS200−500,WESUS 1,000-3,000.
- Chromosome Analysis (15% share) – 5.5% CAGR. Karyotyping to confirm 46,XY. Essential first step in DSD evaluation. Cost: US$ 150-500. Availability: most hospitals.
- Imaging Tests (8% share) – 6.0% CAGR. Pelvic ultrasound (identify Müllerian structures, gonads), genitography (urogenital sinus anatomy), MRI (pelvic anatomy). Cost: US$ 300-2,000.
- Others (2% share) – hCG stimulation tests, ACTH stimulation (exclude adrenal causes), urinary steroid profiling.
Application Segmentation
- Hospital (65% share) – Tertiary care centers, academic medical centers, children’s hospitals with pediatric endocrinology, urology, and clinical genetics departments.
- Clinic (25% share) – Specialty endocrinology clinics, DSD multidisciplinary clinics.
- Others (10% share) – Research laboratories, prenatal diagnostic centers, commercial genetic testing laboratories.
Clinical Deep-Dive: Diagnostic Pathway for Suspected 5-ARD
| Step | Test | Key Finding | Indication |
|---|---|---|---|
| 1 | Karyotype | 46,XY | Confirm genetic male with ambiguous genitalia |
| 2 | Testosterone/DHT (baseline or hCG-stim) | Elevated T:DHT ratio (>20-30:1) | Suggests 5-ARD |
| 3 | SRD5A2 gene sequencing | Pathogenic variants (homozygous or compound heterozygous) | Confirms diagnosis |
| 4 | Pelvic ultrasound / MRI | No Müllerian structures (absence of uterus, fallopian tubes) | Excludes other DSD etiologies |
| 5 | Family genetic testing | Carrier status (parents, siblings) | Genetic counseling |
Epidemiology: 5-ARD incidence varies geographically: 1:50,000-1:100,000 in general population; higher in consanguineous populations (e.g., 1:5,000-1:10,000 in Turkey, Egypt, Saudi Arabia, Pakistan). Estimated 2,000-5,000 new cases diagnosed globally annually.
Recent Technical Breakthrough (Q4 2024) – A persistent challenge in hormone testing for 5-ARD has been DHT assay sensitivity and specificity. DHT circulates at 1/10th the concentration of testosterone and cross-reacts with testosterone antibodies in standard immunoassays. Roche introduced a specific LC-MS/MS (liquid chromatography tandem mass spectrometry) assay for DHT with sensitivity to 5 pg/mL (previous assays 20-50 pg/mL) and no cross-reactivity with testosterone (0.1% cross-reactivity vs. 5-10% in immunoassays). The assay enables accurate T:DHT ratio measurement without hCG stimulation in many cases (baseline DHT detectable). Available in Roche Cobas platforms in major reference labs as of 2025.
Typical User Case (Q2 2025) – A newborn (46,XY) presented with ambiguous genitalia (perineoscrotal hypospadias, bifid scrotum, non-palpable gonads). Serum testosterone 250 ng/dL (normal for newborn), DHT 8 pg/dL (normal >30 pg/dL), T:DHT ratio 31:1 (suggestive 5-ARD). SRD5A2 gene sequencing identified homozygous c.680G>A mutation (p.Arg227Gln). Pelvic ultrasound confirmed absence of Müllerian structures. Parents counseled regarding male gender assignment, staged hypospadias repair, testosterone therapy (starting at puberty). Diagnosis enabled appropriate management and genetic counseling for future pregnancies (25% recurrence risk).
Exclusive Observation: The Newborn Screening Opportunity
5-ARD is not currently included in standard newborn screening panels (dried blood spot). However, DSD diagnosis and early appropriate gender assignment require diagnosis in the newborn period. Key opportunities for expanded testing:
| Region | Newborn Screening for DSD | 5-ARD Testing Access | Growth Drivers |
|---|---|---|---|
| United States | No universal screening for DSD | Referral-based (endocrinology consultation) | State advocacy, clinical awareness |
| Europe (select countries) | Some DSD screening pilot programs | Centralized reference labs | Rare disease initiatives |
| Middle East | Higher awareness (higher incidence) | More accessible genetic testing | Consanguinity prevalence |
| South Asia | Limited | Emerging (more genetic testing available) | Cost reduction |
Potential market expansion: If 5-ARD added to newborn screening panels (via genetic testing or hormone assay on dried blood spot), test volumes could increase 10-100x (from ~5,000 suspected cases/year to 1-2 million births screened/year). Estimated incremental market opportunity: US$ 20-50 million annually for testing.
Industry Segmentation: Diagnostic Testing vs. Therapeutic Management
The 5-alpha reductase deficiency market spans diagnostic testing (the focus of this analysis) and downstream therapeutic management (not included in market size):
| Segment | Market Size (2025) | Key Players | Growth |
|---|---|---|---|
| Diagnostic testing (current report) | US$ 320 million | Roche, Merck, reference labs | 7.2% |
| Hormone therapy (testosterone, DHT) | US$ 60 million | Bayer (Testopel), generic | 5-6% |
| Surgical management (hypospadias repair, gonadectomy) | US$ 200+ million | Hospital-based | 4-5% |
| Laser/aesthetic (adjacent, post-treatment) | US$ 100 million (related uses) | Alma, Fotona, Viveve | 8% |
Cost structure (targeted SRD5A2 gene sequencing panel, US$ 200-500 per patient):
| Component | Percentage |
|---|---|
| DNA extraction and library prep | 15-20% |
| Sequencing reagents (Sanger or NGS) | 25-35% |
| Sequencing instrument depreciation | 10-15% |
| Bioinformatics analysis (variant calling, interpretation) | 15-20% |
| Clinical report and certification | 10-15% |
| Margin (lab) | 15-25% |
Additional Market Dynamics: The 5-alpha reductase deficiency diagnostic market faces challenges from (1) low disease awareness (many cases undiagnosed), (2) limited availability of DHT assays (many labs do not offer LC-MS/MS DHT), (3) high cost of genetic sequencing in low-resource settings, (4) cultural/social sensitivities regarding DSD diagnosis. However, the combination of declining sequencing costs, expanding newborn screening programs, increased DSD awareness, and genetic testing integration into routine pediatric care positions the 5-ARD diagnostic market for sustained 6-8% annual growth through 2032.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
